Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy

Table 2 Characteristics of the patients treated with sitagliptin or anagliptin for 52 weeks (n = 307)

	Anagliptin (n = 148)		P	Sitagliptin (n = 159)		P	P^a
	Baseline	52 weeks	P	Baseline	52 weeks	P	P^a
Body mass index	26.7 ± 3.9	26.5 ± 4.1	0.04	25.8 ± 3.6	25.8 ± 3.8	0.92	0.12
Waist circumference (cm)	94.2 ± 11.1	93.6 ± 10.9	0.30	92.7 ± 9.8	92.4 ± 9.6	0.56	0.69
AST (IU/L)	23 (18–30)	23 (18–29)	0.14	20 (18–25)	21 (18–27)	0.02	< 0.01
ALT (IU/L)	23 (17–34)	22 (14–33)	0.12	18 (15–26)	19 (14–26)	0.42	0.08
γGTP (IU/L)	30 (18–46)	27 (19–42)	0.16	24 (18–35)	24 (18–36)	0.12	0.07
Blood urea nitrogen (mg/dL)	16.7 ± 6.0	16.8 ± 5.3	0.89	17.1 ± 5.6	17.5 ± 5.5	0.30	0.51
Creatinine (mg/dL)	0.84 ± 0.27	0.86 ± 0.29	0.04	0.86 ± 0.29	0.87 ± 0.29	0.17	0.34
eGFR (mL/min/1.73 m²)	68.9 ± 20.7	66.8 ± 20.6	0.02	66.9 ± 18.5	65.7 ± 18.4	0.06	0.44
Total cholesterol (mg/dL)	190 ± 30	186 ± 28	0.02	186 ± 29	191 ± 27	0.01	< 0.01
LDL cholesterol (mg/dL)	112 ± 22	108 ± 22	0.01	110 ± 22	112 ± 21	0.15	< 0.01
HDL cholesterol (mg/dL)	54 ± 14	53 ± 13	0.43	55 ± 13	56 ± 13	< 0.01	0.01
Triglycerides (mg/dL)	136 (98–190)	134 (97–185)	0.80	114 (80–158)	110 (82–160)	0.22	0.55
Fasting glucose (mg/dL)	143 ± 42	147 ± 48	0.18	140 ± 39	146 ± 44	< 0.01	0.47
Insulin (µU/mL)	8.0 (5.7–12.0)	8.5 (5.3–13.3)	0.51	6.9 (4.5–11.0)	7.1 (4.7–11.5)	0.54	0.39
HbA1c (%)	7.1 ± 0.8	7.1 ± 0.9	0.71	6.9 ± 0.7	7.0 ± 0.9	0.04	0.28

Variables are expressed as mean ± SD or medians (interquartile ranges)
AST aspartate transaminase, ALT alanine transaminase, eGFR estimated glomerular filtration rate, γGTP γ-glutamyl transpeptidase
^aFor group difference in absolute change from baseline to 52 weeks

ISSN: 1475-2840